China Unveils Major Pharmaceutical and Medical Device Reforms to Drive Innovation

On December 30, 2024, the General Office of China’s State Council issued Document No. 53, outlining comprehensive reforms aimed at strengthening the regulation of pharmaceuticals and medical devices. These reforms seek to foster innovation, enhance regulatory efficiency, and position China as a global leader in the pharmaceutical industry.

Strategic Vision and Timelines

The reforms are part of a broader strategy to ensure the safety, accessibility, and global competitiveness of pharmaceutical and medical devices. By 2027, regulatory systems will better support industry growth with more streamlined approval processes and advanced oversight mechanisms.

By 2035, China aims to achieve regulatory modernization that meets the needs of both innovation and industry.

Support for Innovation

The reforms emphasize accelerated pathways for critical innovations, including personalized guidance for groundbreaking drugs and high-priority medical devices. Traditional Chinese medicine (TCM) receives dedicated attention, with plans to integrate clinical experience and modern evaluation methods.

Intellectual property protections will be strengthened, with measures like data exclusivity and market exclusivity for rare disease treatments and pediatric drugs.

Streamlined Approval Processes

Key reforms target the efficiency of drug and device approvals. In selected regions, clinical trials for innovative drugs approval times will be halved from 60 to 30 working days. The review and approval of medical device clinical trials will also be halved from 60 to 30 working days.

Faster review processes will prioritize treatments for rare diseases, critical care devices, and cutting-edge technologies like artificial intelligence in medical equipment.

Integration with Global Standards

International alignment is a cornerstone of the reforms. China plans to harmonize its regulatory framework with global standards, facilitating simultaneous global development and registration of innovative drugs.

Efforts to expand international clinical trials and simplify import/export processes reflect a commitment to collaboration and accessibility.

Enhanced Oversight and Digital Tools

Advanced digital tools will play a pivotal role in improving transparency, efficiency, and compliance. The introduction of a national smart regulatory platform will enhance data management, ensure full lifecycle traceability, and streamline processes such as inspections and registrations.

Opportunities for Global Businesses

These reforms present significant opportunities for international businesses and compliance managers seeking to engage with the Chinese market. The shift toward harmonization with global practices, combined with a more efficient regulatory environment, signals a more accessible and innovation-friendly market for pharmaceuticals and medical devices.

Further Information

To read the document Reform of Drug and Medical Device Supervision and Promoting High Quality Development of the Pharmaceutical Industry, announced by the NMPA, please click here.